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Abstract The primary headaches, migraine with (MA)
and without aura (MO) and cluster headache, all carry a
substantial genetic liability. Familial hemiplegic migraine
(FHM), an autosomal dominant mendelian disorder classi-
ﬁed as a subtype of MA, is due to mutations in genes
encoding neural channel subunits. MA/MO are considered
multifactorial genetic disorders, and FHM has been pro-
posed as a model for migraine aetiology. However, a review
of the genetic studies suggests that the FHM genes are not
involved in the typical migraines and that FHM should be
considered as a syndromic migraine rather than a subtype
of MA. Adopting the concept of syndromic migraine could
be useful in understanding migraine pathogenesis. We hy-
pothesisethat epigenetic mechanismsplay an important role
inheadache pathogenesis.Abehaviouralmodelisproposed,
wherebytheprimaryheadachesareconstruedasbehaviours,
not symptoms, evolutionarily conserved for their adaptive
value and engendered out of a genetic repertoire by a net-
workofpatterngeneratorspresentinthebrainandsignalling
homeostatic imbalance. This behavioural model could be
incorporated into migraine genetic research.
Keywords Migraine  Tension-type headache 
Cluster headache  Genetics  Epigenetics
Introduction
The genetics of the primary headaches scored recent
scientiﬁc successes due to the unravelling of the genetics of
FHM. Deciphering of the patho-physiological mechanisms
of these common diseases promises to bring the much
needed knowledge for pharmacological treatments and
therapeutic interventions. There are however also problems
and controversies, some not solved by the genetic studies
performed to date. The following is a brief subjective
review of the available evidence, suggesting a role for
epigenetic mechanisms and ending with the proposal of a
behavioural model of the primary headaches possibly
useful for the genetic studies.
Primary and secondary headaches: symptoms,
syndromes or diseases? Idiopathic and syndromic
migraines
Headaches/migraines are plagued by problems of deﬁni-
tion: these terms describe symptoms (a feature which
indicates a condition of disease, in particular one apparent
to the patient, CED 2003), and at the same time, distinctive
syndromes (a group of symptoms which consistently occur
together) [1]o rdiseases (a disorder of structure or function
in a human, animal, or plant, especially one that pro-
duces speciﬁc symptoms) [1] with recognisable diagnostic
features, internationally deﬁned [2]. The problems encoun-
tered with deﬁnitions become evident when dealing with
primary or secondary headaches, and when considering
idiopathic and syndromic migraines. Secondary headaches
are those in which attacks occur due to a recognisable
cause or disease, which itself represents the primary cause
of the attacks. Syndromic migraines, contrasted with the
idiopathic ones, are those in which attacks of migraine,
clinically barely or not distinguishable from those occur-
ring in the primary migraines, occur compounded with
involvement of other systems. Syndromic migraines are
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potentially useful in the exploration of headache patho-
genesis, has been applied to conditions such as deafness,
visual loss and epilepsy, but has no place in the HCS
classiﬁcation that classiﬁes headache attacks and not dis-
eases, albeit distinguishing between primary and secondary
headaches. These considerations may apply to the genetics
of the primary headaches, since by adopting the HCS
(2004), we consider symptoms, not diseases (much as if,
studying the genetics of diabetes mellitus, we adopted a
classiﬁcation of the hyperglycemias).
Genetic epidemiology of the typical migraines
The typical primary migraines (MO and MA) all have a
substantial risk of familial recurrence. When estimating the
population relative risk of migraine in speciﬁed groups of
relatives (i.e. the ratio between the probability that a rela-
tive versus a random member of the population is affected),
ﬁrst-degree relatives of migraine without aura probands
have 1.9 times the risk of MO and 1.4 times the risk of MA,
whereas ﬁrst-degree relatives of MA probands have nearly
four times the risk of MA and no increased risk of MO [3].
Since a family aggregation is implied when the risk ratio
exceeds one, this conﬁrms the familial liability for the
migraines, even though familiarity is not yet heredity. A
further analysis showed however that spouses of MO pro-
bands have 1.4 times the risk of MO, and spouses of MA
probands have no increased risk of MA [3], thus backing a
hereditary liability for MO and especially MA. Twin
studies concur with this increased familial liability. Con-
cordance rates for migraine are consistently higher among
monozygotic (MZ) than dizygotic (DZ) twins. In particu-
lar, heritability estimates were around 52% in female twin
pairs raised together or apart since infancy. In MZ Danish
twin pairs, liability to MO resulted from additive genetic
effects (61%) and from individual-speciﬁc environmental
effects (39%), while in MA, correlation in liability was
0.68 in MZ and 0.22 in DZ, with heritability estimated at
0.65. Therefore, twin studies reveal that approximately
one-half of the variation in migraine is attributable to
additive genes, while the remainder is caused by unshared
rather than shared environmental factors between twins
[4, 5]. Several studies have analysed pedigrees with
migraine, segregation analysis being performed to discover
the genetic transmission pattern. Studies at ﬁrst envisioned
migraine as a simple mendelian disorder, inherited
according to monogenic rules of transmission. Various
modes of inheritance, autosomal dominant with female
preponderance, possibly sex determined; autosomal reces-
sive with 70% penetrance; polygenic; maternal and
X-linked transmissions have been proposed, or rejected
[6, 7]. Finally, based on complex segregation analysis, a
multifactorial inheritance was considered the most likely
pattern even in high-risk families with MA [8]. A single
gene was considered unlikely, but, notably, in some fam-
ilies, a mendelian or mitochondrial inheritance could not be
excluded [3]. Currently, migraine is widely considered a
complex disease with multifactorial inheritance. This type
of inheritance applies to many complex/quantitative traits,
i.e. traits that vary continuously in a phenotypic range, and
in which variation is quantitative, not qualitative. Examples
of quantitative traits are height, body weight, etc. Such
traits are inﬂuenced by multiple genes (each a quantitative
trait locus QTL), each having a small quantitative effect
and interacting with the environment. However, there is
still no unequivocal evidence that migraine as a quantita-
tive trait varies continuously in the general population, and
moreover, genetic variation underlying a continuous char-
acter distribution can result from segregation at a single
locus too. Therefore, considering migraine as a quantitative
trait may still be unwarranted.
The primary headaches also display considerable
comorbidity, rarely incorporated into genetic studies. MA
is comorbid with hypomania, depression and anxiety, and
MO with phobia, panic and major depression. Other
comorbidities are stroke, dyslipoproteinemias, essential
tremor, paroxysmal dyskinesia and epilepsy. Merikangas
et al. in a longitudinal genetic epidemiology study found
that migraine was associated with mood disorders and drew
attention to the fact that age at onset of anxiety disorders
preceded, while onset of affective disorders followed that
of migraine, ﬁndings consistent with a syndromic rela-
tionship between migraine and anxiety/depression [9].
These ﬁndings have been replicated, maternal depres-
sion being signiﬁcantly associated with development of
migraine in children [10]. Asthma, rhynitis and allergic
bronchitis are also important comorbidities recurring in
migraine families [11–13]. These comorbid clinical fea-
tures should be properly incorporated in the genetic studies
of the primary headaches.
Mendelian migraines? The genetics of FHM
and their putative relationship with the typical
migraines MA/MO
Migraines may be multifactorial, but mendelian migraines,
i.e., migraines that conform to a mendelian type of genetic
transmission, do exist. FHM is classiﬁed as a subtype of
migraine with aura in the HCS (2004), and it conforms to
an autosomal dominant pattern of hereditary transmission.
Joutel et al. mapped FHM to chromosome 19, and in 1996
the ﬁrst FHM gene, CACNL1A4, later termed CACNA1A,
encoding the alpha1A subunit of the P/Q neural calcium
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episodic ataxia type 2 (EA2) phenotypes [14, 15]. Spi-
nocerebellar atrophy type 6 (SCA6) was added to the FHM
and EA2 phenotypes in 1997 [16]. Thus, FHM 1, EA2 and
SCA6 are all allelic channelopathies, with missense
mutations mostly accounting for FHM, mutations disrupt-
ing the reading frame for EA2 and polyglutamine
expansions in the COOH gene terminal for SCA6. The
phenotypic spectrum of the CACNA1A mutations was at
ﬁrst believed to consist either of pure FHM or of FHM
associated with cerebellar atrophy. Why some mutations
originate pure FHM while others elicit progressive or
intermittent cerebellar features remains unclear [17]. Ictal
coma after trivial trauma and essential tremor were asso-
ciated clinical features in families harbouring particular
CACNA1A mutations. The phenotypic spectrum of the
CACNA1A mutations has further expanded to include
ataxia induced by fever or high temperature [18], childhood
epilepsy [19,20] and status epilepticus [21], paroxysmal
paranoid psychosis with anxiety [22], benign paroxysmal
torticollis of infancy, considered a migraine equivalent
[23], and even myasthenic syndrome [24], since CACNA1A
is also expressed on presynaptic neuromuscular junction
terminals where it modulates transmitter release [25] even
in the absence of any morphological changes in the junc-
tion or muscle weakness [26].
The paroxysmal clinical features of migraine, ataxia and
epilepsy, together with the consideration that CACNA1A
speciﬁes for a calcium channel and that in the tottering and
leaner mouse with epilepsy and ataxia, similar mutations
are found in the mouse homologue of the calcium channel
alpha1A subunit gene, led to the proposal that migraine be
considered a calcium channelopathy [27]. The concept of
migraine as a brain channelopathy ﬁts well with the phe-
nomenon of spreading depression [28], implicated in
migraine attack pathophysiology. It is now accepted by the
scientiﬁc community as an explicative model for migraine.
However, the available genetic evidence is controversial or
negative (see below).
FHM was soon proved to be genetically heterogeneous,
some families linking to chromosome 1 [29,30], and a
second gene, ATP1A2, encoding the alpha2 subunit of the
Na/K ATPase, was discovered in Italian families and
accounting for a phenotype of pure FHM (FHM 2) [31].
New mutations were found in FHM 2 pedigrees [32], and
soon the phenotypic spectrum of FHM 2, initially thought
to be conﬁned to pure FHM, broadened to include such
features as coma, triggered by minor head trauma and
angiography [33], recurrent comas [34] and epilepsy,
namely benign familial infantile febrile convulsions [35].
Finally, cerebellar ataxia associated with epilepsy and
mental retardation was described in an Italian FHM 2
family [36,37], ﬁndings later conﬁrmed by Spadaro et al.
and Vanmolkot et al. in other families [38, 39]. Phenotypes
of alternating hemiplegia of childhood [40–42] and basilar
migraine [43] described with ATP1A2 mutations further
enlarged the clinical spectrum of FHM 2. Variability within
the same family is notable, with FHM, cerebellar ataxia,
recurrent paroxysmal dystonia and mental retardation all
recurring together [42].
Lastly, mutations in the neuronal voltage-gated sodium
channel SCN1A were reported by Dichgans et al. [44]t o
account for a phenotype of pure FHM (FHM 3), and there
are still FHM families without mutations in any of the
previously described genes, implying further genetic het-
erogeneity. Sporadic patients with HM, more common in
clinical practice, also present problems, since mutations in
the known FHM genes are only rarely encountered in this
population [45].
An important corollary of the genetic discoveries
obtained in the FHM was the proposal to consider FHM as
a model for the typical migraines MO and MA [27]. This
spurred the search for the involvement of FHM genes in
MO/MA. Up to now the effort has been largely unre-
warding. This in our opinion is also due to the
misclassiﬁcation of FHM as a subtype of MA [2], whereas
FHM represents a syndromic migraine (see below). Some
evidence in favour of linkage of typical migraines to the
FHM locus on chromosome 19 was initially offered by
May et al. [46], Nyholt et al. [47] and Terwindt et al. [48].
However, early negative studies [49–51] were later sub-
stantiated by systematic screening investigations of the
CACNA1A in families with MO and/or MA [52–55], and to
date, mutations in CACNA1A have never been demon-
strated in kindreds without hemiplegic migraine, with or
without aura. The same negative considerations apply to
ATP1A2. Earlier evidence in favour of a role of the Chrlq3l
locus or ATP1A2 gene in the typical migraines [56, 57] was
superseded by negative ﬁndings and absent ATP1A2
mutations in typical migraine only pedigrees, even those
displaying an apparently autosomal dominant mode of
inheritance [58–61]. The FHM 3 SCN1A gene was dis-
covered too recently for any conclusive study. Von Brevern
et al. [62] however failed to ﬁnd any CACNA1A, ATP1A2
or SCN1A mutations in patients with migrainous vertigo.
Thus, there is no current evidence that the genes causing
FHM represent major susceptibility loci for the typical
migraines.
Does such negative genetic evidence imply that FHM is
not a useful model for migraine etiology? Several reviews
of migraine pathogenesis apply the FHM model of neural
channelopathy to the typical migraines. While such models
are not justiﬁed genetically, it may be contended that FHM
is nonetheless helpful in elucidating the pathophysiology of
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to apply to several clinical conditions all characterised by
headache attacks of the migraine type. Migraine-like
attacks indeed are found not only in the typical migraines,
but also in other conditions, diseases or syndromes, in
which they occur together with symptoms and signs of
multisystem nervous or extra-nervous involvement. These
‘‘syndromic migraines’’ thus display bona ﬁde migraine
headache attacks at some times in their clinical course, and
most of them have a genetic basis (Table 1). FHM is also
characterised by multisystem neurologic involvement
(migraine, hemiplegia, ictal recurrent comas, cerebellar
atrophy, mental retardation, epilepsy, movement disorders,
myasthenic syndrome, etc.), and therefore we make a plea
for FHM to be considered more appropriately as a syn-
dromic migraine and not a subtype of MA, as with the
current HCS classiﬁcation (2004).
Linkage and association studies in the typical migraines
Several studies on the genetics of the typical migraines MO
and MA applied genetic association, linkage and genome
wide scanning methods. Most of these studies resulted in
ﬁndings that either lack veriﬁcation or are controversial. For
MA, a genome wide scan on 50 multigenerational families
in Finland identiﬁed a susceptibility locus on chromosome
4q24 [70]. Other loci for MA have been reported on chro-
mosome 11q24 in Canadian families with an autosomal
dominant transmission pattern [71], and on chromosome
15q11–q13 to a genomic region containing genes encoding
for GABA-A receptors in ten Italian families again dis-
playing an autosomal dominant transmission pattern [72].
For MO, or for pedigrees with MO mixed with MA,
susceptibility loci have been reported on chromosome
6p12.2–p21.1 in Sweden [73], chromosome 5q21 [74],
chromosome 14q21.2–q22.3 in an Italian family with MO
[75], chromosome Xq24–28 in two large Australian
pedigrees [76] and chromosome 19p13.3/2 to the insulin
receptor gene INSR [77]. While many of such ﬁndings have
still to be replicated, in some cases (the INSR gene)
sequence studies have given negative results [78].
Other studies have examined candidate genes, implying
that a pathogenetic (and a priori) hypothesis was formu-
lated beforehand. This may be risky, considering that
the pathogenesis of the migraine headaches is still imper-
fectly understood. Candidate genes explored were the
mitochondrial DNA (mtDNA), or genes involved in pro-
thrombotic or cardiovascular disease, or in the metabolism
of biologic amines such as dopamine or serotonin, or in a
variety of other metabolic systems. Several of the studies
applied to mtDNA genes have yielded negative results,
even though in some families migraine was reported to
segregate with the Leber mtDNA 14484 mutation [79], and
mtDNA mutations and haplotypes (haplotype U) have been
associated with juvenile migraine stroke [80, 81] and with
cyclic vomiting, considered a migraine equivalent in the
pediatric population [82–84]. Contrasting results for genes
involved in prothrombotic/cardiovascular risk, and for
those involved in the metabolism of the biological amines
serotonin and dopamine, or in several other metabolic
pathways are summarised in Tables 2, 3, 4, and 5.
Finally, a few studies have focused on the genetics of
the chronic headaches, a major social problem, since these
chronic headaches are often associated with drug abuse and
afﬂict a remarkable percentage of the general population.
Chronic tension-type headache displays a substantial
familial recurrence, with lifetime relative risk estimated at
3.87 for parents and 3.53 for children of probands; the risk
is greater for females (3.35) than for males (2.59) [85].
A genetic association study of chronic headache with drug
abuse versus the dopamine metabolism genes by Cevoli
et al. [86] found that allele 4 of the exon III VNTR poly-
morphism of the dopamine receptor 4 gene DRD4 was
associated with chronic daily headache, and allele 9 of the
dopamine transporter gene SLC6A3 was more common in
Table 1 A list of proposed (and provisional) syndromic migraines
Syndromic migraines Genes (chromosome) involved Migrainous features (references)
MELAS (mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes)
MTTL1, MTTQ, MTTH, MTTK, MTTS1,
MTND1, MTND5, MTND6, and MTTS2
(mtDNA)
Most frequent symptom: episodic sudden
headache with vomiting and convulsions
[63, 64]
CADASIL (cerebral arteriopathy, autosomal
dominant, with subcortical infarcts and
leukoencephalopathy)
NOTCH 3 (19p13.2–p13.1) MA in 22% [65]; migraine in 38% [66]
HERNS (retinopathy, vascular, with cerebral and
renal involvement and Raynaud and migraine
phenomena)
TREX1 (3p21.3–p21.2) Migraine in 70% [67]
CCM (familial cerebral cavernous malformations) KRYT 1 (7q11.2–q21) Convulsions and migraine attacks [68, 69]
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episodic migraine.
Genetics of tension-type headache
Remarkably, apart from an epidemiological genetic study
that demonstrated a familial aggregation for chronic ten-
sion-type headache [85], there are no other genetic studies
of this common disorder.
Genetics of cluster headache
Cluster headache (CH) has long been considered a sporadic
disease. In recent decades, however, a familial recurrence
has been appreciated, and the new HCS classiﬁcation
(2004) now states that CH may be transmitted as an auto-
somal dominant disease in about 5% of cases. Several CH
cases have been reported among monozygotic twins and in
family pedigrees [129–137], and family studies indicate that
I-degree relatives of CH probands carry a 5- to 18-fold, and
Table 2 Prothrombotic and
cardiovascular risk genes and
typical migraine genetics
Prothrombotic/vascular risk genes
or mutations examined
Phenotypes
LDL receptor (19p13.2) Associated with MO [87]; not associated [88]
Factor V R/Q 506 (Leiden mutation) Associated with MA [89]
Not associated with migraine stroke [90]; not
associated with MA/MO [91]; not associated with
juvenile MA [92]
Factor II 20210 G/A Not associated with MA/MO [91]
Not associated with migraine stroke [93]
Factor XIII Val 34 Leu Not associated with migraine [94]
Decanucleotide insertion/deletion factor VII
promoter
Not associated with MA/MO [91]
Alloantigenic platelet systems HPA-1 and HPA-2 Not associated with MA/MO [91]
Deﬁcit of protein S Associated with MA [89]
Angiotensin converting enzyme (ACE) Allele D associated with MO and more frequent
migraine attacks [95]
Endothelial NO synthase inducible (NOS3; iNOS) Not associated with migraine [96, 97]
Endothelin receptor A (ETA-231 A/G)
polymorphism
Allele G protecting from migraine [98]
MTHFR (methylene-tetra-hydrofolate reductase)
C677T/A1298C
Homozygous mutation associated with MA [99],
associated with MA [100]; risk for MA,
modulated by thymidilate synthase gene [101]
Table 3 Serotonin metabolism
genes and typical migraine
genetics
Serotonin metabolism
genes examined
Phenotypes
5-HTSERT (17q11.2–12) Allelic association with MO (increase of allele STin2.12 + decrease of allele
STin2.10) and MA (same + increase of allele Stin2.9) [102]; 5HT-TLPR
with MA [103]
Allelic association with migraine (allele Stin2.10) [104]; borderline
association with migraine [105]
No association/linkage with migraine [106, 107]
5-HT2A (13q14–21) Allelic (allele C) association with migraine aura [108]
No association with migraine [105, 106, 109, 110]
5-HT1B (6q13) No association with migraine [106, 110, 111]
5-HT1D (1p36.3–34.3) No association with migraine [106, 110, 111]
5-HT2B (2q36.3–q37.1) No association with migraine [106, 110, 111]
5-HT2C (Xq22–25) No association with migraine [106, 110, 111]
5-HT1B (6q13) No association with therapeutic response to triptans [112, 113]
5-HT1F (3p12) No association with therapeutic response to triptans [112, 113]
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the disease [138–141]. CH has been considered a probable
autosomal dominant disease with a penetrance of 0.3–0.34
in males and 0.17–0.21 in females [142]. The exact trans-
mission pattern is however still debated [143, 144], and an
autosomal recessive pattern has been advocated in certain
families [137]. Several candidate genes have been analysed,
in particular mtDNA mutations [145–148], HLA antigens
[149–151] and CACNA1A polymorphisms [152, 153],
usually with negative or controversial results. Other genes,
such as the NO synthases NOS1, NOS2A and NOS3 [154],
the elusive amine gene cluster [155], the CLOCK gene
involved in the regulation of circadian rhythms [156,157]
and the hemochromatosis gene [158], have been found not
associated with CH. Recently, an association between CH
and a polymorphism in the hypocretin receptor 2 gene
HCRTR2 was reported by Rainero et al. [159], possibly
accounting for the circadian recurrence of the CH attacks.
Such an association, while conﬁrmed by Schu ¨rks et al.
[160], was rejected in a European multicentric study [161].
Recently, reports of CH associated with hemiparesis during
the attacks suggested a relationship with FHM and ionic
channelopathies [162]. Preliminary genic expression stud-
ies instead documented the activation of proinﬂammatory
genes during the CH attack [163].
Genetics and epigenetics
Epigenetics is the study of the changes in DNA and DNA-
binding proteins that, albeit altering the structure of chro-
matin, do not modify the nucleotide sequence of DNA. The
remarkable feature here is that some of these modiﬁcations
may be associated with heritable changes in gene function.
Commonly held concepts of heredity indeed pit envi-
ronmental inﬂuences (nurture) against genetic background
(nature) as totally separate causative factors. Genetic
advances themselves have however demonstrated that the
hereditary transmission of biological changes not encoded
in the DNA sequence and dictated by environmental
inﬂuences is possible. This part of genetics, called epige-
netics, has received little or no attention in the genetic
studies of the primary headaches. It is the contention of the
author however that future epigenetic studies will account
for several hereditary features of the primary headaches, in
particular their comorbidities.
All those (meiotic and mitotic) modiﬁcations in gene
expression that are heritable but not encoded in the DNA
sequence are deﬁned as epigenetic. Molecular mechanisms
implicated include (1) methylation of cytosine residues at
C5 in dinucleotide CpG sites (localised especially in pro-
moters of well over 40% of the genes and that, when
Table 4 Dopamine metabolism
genes and typical migraine
genetics
Genes examined Phenotypes
Dopamine receptor 2 (DRD2) Allelic association (allele NcoI) with MA comorbid
with anxiety/depression [114]
Allelic association (allele 1) with yawning/nausea
during attack of MO [115]
No allelic association (allele NcoI) with MA [116]
No allelic association with MO/MA [107, 117, 118,
119]
Dopamine receptors 1, 3, 4, 5 (DRD1, DRD3,
DRD4, DRD5)
No allelic association with migraine [115, 117, 120]
Dopamine transporter (DAT) Association with chronic daily headache with drug
abuse [86]
COMT; MAO-A No association with migraine [117, 121]
Dopamine-betahydroxylase (DBH) Association with migraine [107], especially males with
MA [122]
No association [123]
Table 5 Other genes
implicated in typical migraine
genetics
Genes examined Phenotypes
Androgen/progesterone receptors Androgen receptor not associated; progesterone receptor
associated with migraine [124]
K channel KCNN3 Allelic association (CAG repeats) with MO/MA [125]
Not associated (CAG repeats) [126]
Cytotoxic T lymphocyte antigen 4
(CTLA-4)
Not associated with migraine [127]
HLA-DRB1 Allelic association with MA [128]
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of RNA interference, whereby microRNAs silence gene
expression; (3) histone (DNA associated proteins) changes:
activation or inactivation of genomic regions according to
the ‘‘histone code’’. All of these mechanisms result in the
expression or silencing of genes, and underlie such phe-
nomena as inactivation of the X chromosome and genomic
imprinting. Several epigenetic diseases are already known
that may be inherited through the somatic and the germinal
line: fragile X syndrome, in which ATRX gene mutations
modify the methylation pattern of ribosomial RNA and, by
methylation of CGG expansions in the FMR1 gene, silence
the gene; the Angelman and Prader-Willi, and Rett syn-
dromes; also, many colonic cancers and leukemias.
Important epigenetic differences that increase with age are
found even between monochorial twins [164]. Notably,
epigenetic modiﬁcations may increase with age and may
also be prevented through interventions directed at DNA or
histone methylation (with azanucleotides, antisense oligo-
nucleotides, histone deacetylase). Even more remarkably,
there is some evidence that lifestyles and even diet may
play a role [165].
Epigenetic models for the primary headaches?
There is consistent evidence that behavioural differences
typical of speciﬁc inbred animal strains are the conse-
quence of environmental inﬂuences acting especially
during development rather than DNA changes. Mice strains
with decreased environmental exploration behaviour (B6
strain) develop enhanced exploratory behaviour if nurtured
in their ﬁrst 3 months of life by BALB dams, a strain
displaying intense exploratory behaviour; changes in
behaviour appear to be linked to the type of maternal care,
particularly licking of the pup by the mother, a behaviour
demonstrated to affect the status of the endocrine stress
system in mice [166]. Weaver et al. [167] showed how
maternal care in the rat (licking and grooming the pup)
modiﬁes the methylation pattern of the promoter of the
glucocorticoid receptor gene in the hippocampus; such
epigenetic changes, evident from the ﬁrst week of life,
persist throughout the animal’s life but are reversible upon
treatment with histone deacetylase inhibitors or upon
intracerebral administration of methionine (an intervention
that modiﬁes the methylation pattern) [168].
Stress plays a remarkable role in the development of the
nervous system: removal of rat pups from the mother causes
reduced neurogenesis in the adult hippocampus through
steroid-dependent mechanisms [169], and alters serotoner-
gic transporter densities and serotonergic 1A receptors in
the rat brain [170]. Administration of steroids to the mother
before delivery causes changes in behavioural patterns in
juvenile rats [171], and maternal deprivation in the imme-
diate post-natal period modiﬁes locomotor and steroid
release patterns in the adult rat [172]. Epigenetic mecha-
nisms also seem relevant for the formation of memory
traces [173] and more generally for cognitive development
[174]. Epigenetic mechanisms have been hypothesised for
psychiatric disorders [175, 176] and many complex and
multifactorial diseases affecting the brain or the inﬂam-
matory and immune systems [177–179].
There are still no studies of epigenetic mechanisms in
the primary headaches. When considering, however, the
important maternal inﬂuence in migraine genetics; the
consistent and inherited co-morbidities especially for psy-
chiatric and inﬂammatory-immune disorders; twin studies
documenting that only about half of the variability is due to
‘‘genetic’’ factors; it is possible to envision that epigenetic
mechanisms, especially those acting during nervous system
development in early infancy and childhood, play a role
in the heritability and pathophysiology of the primary
headaches. Preliminary studies have already analysed
attachment styles in adult migraineurs [180, 181], and a
prospective investigation demonstrated correlations between
events suffered during pregnancy and early life, and quality
of adult life 31–33 years later [182]. It is reasonable
to suggest that early life factors and attachment styles
between mother and child represent determinants of epi-
genetic changes relevant in migraine pathogenesis. Such
early pre- and post-natal environmental behavioural factors
could be usefully analysed to deﬁne endophenotypes of
adaptive behaviour useful in the genetic studies of the
primary headaches.
Final comments: a behavioural model of the primary
headaches as ﬁght-or-ﬂight response and sickness
behaviour to be incorporated into genetic research
Consideration of epigenetic mechanisms may help in
analysing behaviours during the headache attacks. Any
genetic studies are ultimately dependent upon the deﬁnition
of the phenomenon taken into consideration, and on how it
is conceptualised. Therefore, studies have to rely upon
conventional diagnostic criteria, in turn based on a priori
interpretations. Most genetic studies have been performed
within the frame of migraine interpreted simply as a ‘‘pain’’
trait with multifactorial inheritance. In a ‘‘harlequin’’
model, several genetic factors, each one having a small
speciﬁc weight, interact with environmental factors to
determine the migraine attack. Such a model should how-
ever be better tailored to suit phenomena such as the
migraine attack and the migraine diseases that are really
behavioural ‘‘processes’’ with an intrinsic logic of their
own [183], one that is consistent within attacks, within
J Headache Pain (2008) 9:57–69 63
123patients and within populations. There is a need to con-
ceive of the primary headaches along more useful scientiﬁc
lines. Consistently lacking in the genetic studies is for
instance any consideration of migraine as a behavioural
response to environmental and/or endogenous triggers, a
view that has scientiﬁc support [184] and that we recently
revised to accomodate a Darwinian perspective [185].
According to our view, migraine and other primary head-
aches such as CH are behaviours, not symptoms,
evolutionarily conserved for their adaptive value and
engendered out of a genetic repertoire by networks of
pattern generators present in the brain. These neural net-
works serve the homeostasis of the brain, with migraine
pain considered a kind of visceral pain signalling homeo-
static imbalance. The behavioural repertoire enacted during
the migraine attack, complete with its full panoply of pain,
cognitive, autonomic, motor, etc., symptoms and signs, is
comparable to that deﬁned as sickness behaviour and
already known to develop in all mammals and other ani-
mals following challenge with infective and other
pathogenic agents [186]. In contrast, behaviour during the
CH attacks [187] resembles the ﬁght-or-ﬂight response of
hypothalamic animals. These behaviours during the head-
ache attacks really represent ‘‘healing’’ processes, and
migraine may even be evolutionarily advantageous [188].
Thus, what is relevant in this new behavioural model is not
the manifestations of the attack, but the factors triggering
it, that, migraine being of the brain, must relate to still
unknown disturbances of brain homeostasis [185].
Accordingly, it is these triggering factors rather than the
manifestations during the attacks that may represent the
features most relevant for a true dissection of the genetics
of the primary headaches.
Acknowledgments I wish to thank Ms. A. Lafﬁ for help with the
manuscript, and A. Collins for revising the English text. Supported by
MIUR grants. This review results from the lesson of the Author at the
Master in Headache Medicine, Sapienza University of Rome, during
the Academic Year 2007–2008.
References
1. The Compact English Dictionary, IInd edn. Oxford University
Press, Oxford, pp 1–1378
2. Headache Classiﬁcation Subcommittee of the International
Headache Society (2004) The international classiﬁcation of
headache disorders. Cephalalgia 24:1–160
3. Russell MB, Iselius L, Olesen J (1996) Migraine without aura
and migraine with aura are inherited disorders. Cephalalgia
16:305–309
4. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB (1999)
The inheritance of migraine with aura estimated by means of
structural equation modelling. J Med Genet 36:225–227
5. Russell MB, Ulrich V, Gervil M, Olesen J (2002) Migraine
without aura and migraine with aura are distinct disorders.
A population-based twin survey. Headache 42:332–336
6. Devoto M, Lozito A, Staffa G, D’Alessandro R, Sacquegna T,
Romeo G (1986) Segregation analysis of migraine in 128 fam-
ilies. Cephalalgia 6:101–105
7. Mochi M, Sangiorgi S, Cortelli P, Carelli V, Scapoli C, Crisci
M, Monari L, Pierangeli G, Montagna P (1993) Testing
models for genetic determination in migraine. Cephalalgia
13:389–394
8. Ulrich V, Russell MB, Ostergaard S, Olesen J (1997) Analysis
of 31 families with an apparently autosomal-dominant trans-
mission of migraine with aura in the nuclear family. Am J Med
Genet 74:395–397
9. Merikangas KR, Merikangas JR, Angst J (1993) Headache
syndromes and psychiatric disorders: association and familial
transmission. J Psychiatr Res 27:197–210
10. Mortimer MJ, Kay J, Jaron A, Good PA (1992) Does a history of
maternal migraine or depression predispose children to headache
and stomach-ache? Headache 32:353–355
11. Chen TC, Leviton A (1990) Asthma and eczema in children
born to women with migraine. Arch Neurol 47:1227–1230
12. Mortimer MJ, Kay J, Gawkrodger DJ, Jaron A, Barker DC
(1993) The prevalence of headache and migraine in atopic
children: an epidemiological study in general practice. Headache
33:427–431
13. Gurkan F, Ece A, Haspolat K, Dikici B (2000) Parental history
of migraine and bronchial asthma in children. Allergol Immu-
nopathol (Madr) 28:15–17
14. Joutel A, Bousser MG, Biousse V, Labauge P, Chabriat H,
Nibbio A, Maciazek J, Meyer B, Bach MA, Weissenbach J et al
(1993) A gene for familial hemiplegic migraine maps to chro-
mosome 19. Nat Genet 5:40–45
15. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner
PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman
DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker
MH, Ferrari MD, Frants RR (1996) Familial hemiplegic
migraine and episodic ataxia type-2 are caused by mutations in
the Ca2+ channel gene CACNL1A4. Cell 87:543–552
16. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW,
Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC
(1997) Autosomal dominant cerebellar ataxia (SCA6) associated
with small polyglutamine expansions in the alpha 1A-voltage-
dependent calcium channel. Nat Genet 15:62–69
17. Alonso I, Barros J, Tuna A, Seixas A, Coutinho P, Sequeiros J,
Silveira I (2004) A novel R1347Q mutation in the predicted
voltage sensor segment of the P/Q-type calcium-channel alpha-
subunit in a family with progressive cerebellar ataxia and
hemiplegic migraine. Clin Genet 65:70–72
18. Subramony SH, Schott K, Raike RS, Callahan J, Langford LR,
Christova PS, Anderson JH, Gomez CM (2003) Novel CAC-
NA1A mutation causes febrile episodic ataxia with interictal
cerebellar deﬁcits. Ann Neurol 54:725–731
19. Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi
SM, Kullmann DM, Hanna MG (2001) Human epilepsy asso-
ciated with dysfunction of the brain P/Q-type calcium channel.
Lancet 358:801–807
20. Kors EE, Melberg A, Vanmolkot KR, Kumlien E, Haan J,
Raininko R, Flink R, Ginjaar HB, Frants RR, Ferrari MD, van
den Maagdenberg AM (2004) Childhood epilepsy, familial
hemiplegic migraine, cerebellar ataxia, and a new CACNA1A
mutation. Neurology 63:1136–1137
21. Beauvais K, Cave-Riant F, De Barace C, Tardieu M, Tournier-
Lasserve E, Furby A (2004) New CACNA1A gene mutation in a
case of familial hemiplegic migraine with status epilepticus. Eur
Neurol 52:58–61
22. Spranger M, Spranger S, Schwab S, Benninger C, Dichgans M
(1999) Familial hemiplegic migraine with cerebellar ataxia and
paroxysmal psychosis. Eur Neurol 41:150–152
64 J Headache Pain (2008) 9:57–69
12323. Gifﬁn NJ, Benton S, Goadsby PJ (2002) Benign paroxysmal
torticollis of infancy: four new cases and linkage to CACNA1A
mutation. Dev Med Child Neurol 44:490–493
24. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG,
Agius MA, Gomez CM, Richman DP, Wollmann RL (2000)
Presynaptic congenital myasthenic syndrome due to quantal
release deﬁciency. Neurology 57:279–289
25. Plomp JJ, Vergouwe MN, van den Maagdenberg AM, Ferrari
MD, Frants RR, Molenaar PC (2000) Abnormal transmitter
release at neuromuscular junctions of mice carrying the tottering
alpha(1A) Ca(2+) channel mutation. Brain 123(Pt 3):463–471
26. Kaja S, van de Ven RC, Broos LA, Veldman H, van Dijk JG,
Verschuuren JJ, Frants RR, Ferrari MD, van den Maagdenberg
AM, Plomp JJ (2005) Gene dosage-dependent transmitter
release changes at neuromuscular synapses of CACNA1A
R192Q knockin mice are non-progressive and do not lead to
morphological changes or muscle weakness. Neuroscience
135:81–95
27. Terwindt GM, Ophoff RA, Haan J, Sandkuijl LA, Frants RR,
Ferrari MD (1998) Migraine, ataxia and epilepsy: a challenging
spectrum of genetically determined calcium channelopathies.
Dutch Migraine Genetics Research Group. Eur J Hum Genet
6:297–307
28. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S,
Broos LAM, Cesetti T, van de Ven RCG, Tottene A, van der
Kaa J, Plomp JJ, Frants RR, Ferrari MD (2004) A Cacna1A
knockin migraine mouse model with increased susceptibility to
cortical spreading depression. Neuron 41:701–710
29. Gardner K, Barmada MM, Ptacek LJ, Hoffman EP (1997) A
new locus for hemiplegic migraine maps to chromosome 1q31.
Neurology 49:1231–1238
30. Ducros A, Joutel A, Vahedi K, Cecillon M, Ferreira A, Bernard
E, Verier A, Echenne B, Lopez de Munain A, Bousser MG,
Tournier-Lasserve E (1997) Mapping of a second locus for
familial hemiplegic migraine to 1q21–q23 and evidence of
further heterogeneity. Ann Neurol 42:885–890
31. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L,
Morgante L, Ballabio A, Aridon P, Casari G (2003) Haploin-
sufﬁciency of ATP1A2 encoding the Na+/K+ pump alpha 2
subunit associated with familial hemiplegic migraine type 2. Nat
Genet 33:192–196
32. Riant F, De Fusco M, Aridon P, Ducros A, Ploton C, Marchelli
F, Maciazek J, Bousser MG, Casari G, Tournier-Lasserve E
(2005) ATP1A2 mutations in 11 families with familial hemi-
plegic migraine. Hum Mutat 26:281
33. Pierelli F et al (2006) A novel ATP1A2 mutation in a family
with FHM type II. Cephalalgia 26:324–328
34. Echenne B, Ducros A, Rivier F, Joutel A, Humbertclaude V,
Roubertie A, Azais M, Bousser MG, Tournier-Lasserve E
(1999) Recurrent episodes of coma: an unusual phenotype of
familial hemiplegic migraine with linkage to chromosome 1.
Neuropediatrics 30:214–217
35. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J,
Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari
MD, van den Maagdenberg AM (2003) Novel mutations in the
Na+, K+-ATPase pump gene ATP1A2 associated with familial
hemiplegic migraine and benign familial infantile convulsions.
Ann Neurol 54:360–366
36. Cevoli S, Pierangeli G, Monari L, Valentino ML, Bernardoni P,
Mochi M, Cortelli P, Montagna P (2002) Familial hemiplegic
migraine: clinical features and probable linkage to chromosome
1 in an Italian family. Neurol Sci 23:7–10
37. Jurkat-Rott K, Freilinger T, Dreier JP, Herzog J, Gobel H,
Petzold GC, Montagna P, Gasser T, Lehmann-Horn F, Dichgans
M (2004) Variability of familial hemiplegic migraine with novel
A1A2 Na+/K+-ATPase variants. Neurology 62:1857–1861
38. Spadaro M, Ursu S, Lehmann-Horn F, Liana V, Antonini G,
Giunti P, Frontali M, Jurkat-Rott K (2004) A G301R Na+/K+
ATPase mutation causes familial hemiplegic migraine type 2
with cerebellar signs. Neurogenetics 5:177–185
39. Vanmolkot KR, Stroink H, Koenderink JB, Kors EE, van den
Heuvel JJ, van den Boogerd EH, Stam AH, Haan J, De Vries
BB, Terwindt GM, Frants RR, Ferrari MD, van den Maagden-
berg AM (2006) Severe episodic neurological deﬁcits and
permanent mental retardation in a child with a novel FHM2
ATP1A2 mutation. Ann Neurol 59:310–314
40. Bassi MT, Bresolin N, Tonelli A, Nazos K, Crippa F, Baschir-
otto C, Zucca C, Bersano A, Dolcetta D, Boneschi FM, Barone
V, Casari G (2004) A novel mutation in the ATP1A2 gene
causes alternating hemiplegia of childhood. J Med Genet
41:621–628
41. Auvin S, Joriot-Chekaf S, Cuvellier JC, Vallee L (2004)
Familial alternating hemiplegia of childhood or channelopathy?
A report with valuable pathophysiological implications. Dev
Med Child Neurol 46:500
42. Swoboda KJ, Kanavakis E, Xaidara A, Johnson JE, Leppert MF,
Schlesinger-Massart MB, Ptacek LJ, Silver K, Youroukos S
(2004) Alternating hemiplegia of childhood or familial hemi-
plegic migraine? A novel ATP1A2 mutation. Ann Neurol
55:884–887
43. Ambrosini A, D’Onofrio M, Grieco GS, Di Mambro A,
Montagna G, Fortini D, Nicoletti F, Nappi G, Sances G,
Schoenen J, Buzzi MG, Santorelli FM, Pierelli F (2005) Familial
basilar migraine associated with a new mutation in the ATP1A2
gene. Neurology 65:1826–1828
44. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz B,
Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM,
Pusch M, Strom TM (2005) Mutation in the neuronal voltage-
gated sodium channel SCN1A in familial hemiplegic migraine.
Lancet 366:371–377
45. Terwindt G et al (2002) Mutation analysis of the CACNA1A
calcium channel subunit gene in 27 patients with sporadic
hemiplegic migraine. Arch Neurol 59:1016–1018
46. May A, et al (1995) Familial hemiplegic migraine locus on
19p13 is involved in the common forms of migraine with and
without aura. Hum Genet 96:604–608
47. Nyholt DR et al (1998) Familial typical migraine: linkage to
chromosome 19p13 and evidence for genetic heterogeneity.
Neurology 50:1428–1432
48. Terwindt GM et al (2001) Involvement of the CACNA1A gene
containing region on 19p13 in migraine with and without aura.
Neurology 56:1028–1032
49. Hovatta I et al (1994) Familial migraine: exclusion of the sus-
ceptibility gene from the reported locus of familial hemiplegic
migraine on 19p. Genomics 23:707–709
50. Monari L et al (1997) Searching for migraine genes: exclusion
of 290 cM out of the whole human genome. Ital J Neurol Sci
18:277–282
51. Kim JS et al (1998) Familial migraine with vertigo: no muta-
tions found in CACNA1A. Am J Med Genet 79:148–151
52. Brugnoni R et al (2002) Is the CACNA1A gene involved in
familial migraine with aura? Neurol Sci 23:1–5
53. Noble-Topham S et al (2001) Migraine with aura is not linked to
the FHM gene CACNA1A or the chromosomal region, 19p13.
Genomics 78:150–154
54. Jones KW et al (2002) Migraine with aura susceptibility locus
on chromosome 19p13 is distinct from the familial hemiplegic
migraine locus. Neurology 59:1099–1101
55. Wieser T et al (2003) Absence of known familial hemiplegic
migraine (FHM) mutations in the CACNA1A gene in patients
with common migraine: implications for genetic testing. Clin
Chem Lab Med 41:272–275
J Headache Pain (2008) 9:57–69 65
12356. Todt U et al (2005) Rare missense variants in ATP1A2 in
families with clustering of common forms of migraine. Hum
Mutat 26:315–321
57. Lea RA et al (2002) A typical migraine susceptibility region
localizes to chromosome 1q31. Neurogenetics 4:17–22
58. Curtain RP et al (2005) Analysis of chromosome 1 microsatel-
lite markers and the FHM2-ATP1A2 gene mutations in migraine
pedigrees. Neurol Res 27:647–652
59. Jen JC, Kim GW, Dudding KA, Baloh RW (2004) No mutations
in CACNA1A and ATP1A2 in probands with common types of
migraine. Arch Neurol 61:926–928
60. Kirchmann M et al (2006) The CACNA1A and ATP1A2 genes
are not involved in dominantly inherited migraine with aura. Am
J Med Genet B Neuropsychiatr Gen 141:250–256
61. Netzer C et al (2006) Haplotype-based systematic association
studies of ATP1A2 in migraine with aura. Am J Med Genet
141:257–260
62. von Brevern M et al (2006) Migrainous vertigo: mutation
analysis of the candidate genes CACNA1A, ATP1A2, SCN1A,
and CACNB4. Headache 46:1136–1141
63. Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M,
Nonaka I (1992) Mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes (MELAS): a correlative
study of the clinical features and mitochondrial DNA mutation.
Neurology 42:545–550
64. Montagna P, Gallassi R, Medori R, Govoni E, Zeviani M, Di
Mauro S, Lugaresi E, Andermann F (1988) MELAS syndrome:
characteristic migrainous and epileptic features and maternal
transmission. Neurology 38:751–754
65. Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy
TG, Krebs MO, Julien J, Dubois B, Ducrocq X, Levasseur M,
Homeyer P, Mas JL, Lyon-Caen O, Tournier Lasserve E,
Bousser MG (1995) Clinical spectrum of CADASIL: a study of
7 families. Lancet 346:934–939
66. Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J,
Rungger G, Ebke M, Klockgether T, Gasser T (1998) The
phenotypic spectrum of CADASIL: clinical ﬁndings in 102
cases. Ann Neurol 44:731–739
67. Ophoff RA, DeYoung J, Service SK, Joosse M, Caffo NA,
Sandkuijl LA, Terwindt GM, Haan J, van den Maagdenberg
AMJM, Jen J, Baloh RW, Barilla-LaBarca M-L, Saccone NL,
Atkinson JP, Ferrari MD, Freimer NB, Frants RR (2001)
Hereditary vascular retinopathy, cerebroretinal vasculopathy,
and hereditary endotheliopathy with retinopathy, nephropathy,
and stroke map to a single locus on chromosome 3p21.1–p21.3.
Am J Hum Genet 69:447–453
68. Michael JC, Levin PM (1936) Multiple telangiectases of brain: a
discussion of hereditary factors in their development. Arch
Neurol Psychiatry 36:514–536
69. Marini V, Ferrera L, Dorcaratto A, Viale G, Origone P, Mareni
C, Garre ` C (2003) Identiﬁcation of a novel KRIT1 mutation in
an Italian family with cerebral cavernous malformation by the
protein truncation test. J Neurol Sci 212:75–78
70. Wessman M, Kallela M, Kaunisto MA, Marttila P, Sobel E,
Hartiala J, Oswell G, Leal SM, Papp JC, Ha ¨ma ¨la ¨inen E, Broas P,
Joslyn G, Hovatta I, Hiekkalinna T, Kaprio J, Ott J, Cantor RM,
Zwart JA, Ilmavirta M, Havanka H, Fa ¨rkkila ¨ M, Peltonen L,
Palotie A (2002) A susceptibility locus for migraine with aura
on chromosome 4q24. Am J Hum Genet 70:652–62
71. Cader ZM, Noble-Topham S, Dyment DA, Cherny SS, Brown
JD, Rice GP, Ebers GC (2003) Signiﬁcant linkage to migraine
with aura on chromosome 11q24. Hum Mol Genet 12:2511–
2517
72. Russo L, Mariotti P, Sangiorgi E, Giordano T, Ricci I, Lupi F,
Chiera R, Guzzetta F, Neri G, Gurrieri F (2005) A new sus-
ceptibility locus for migraine with aura in the 15q11–q13
genomic region containing three GABA-A receptor genes. Am J
Hum Genet 76:327–333
73. Carlsson A, Forsgren L, Nylander PO, Hellman U, Forsman-
Semb K, Holmgren G, Holmberg D, Holmberg M (2002)
Identiﬁcation of a susceptibility locus for migraine with and
without aura on 6p12.2–p21.1. Neurology 59:1804–1807
74. Nyholt DR, Morley KI, Ferreira MA, Medland SE, Boomsma
DI, Heath AC, Merikangas KR, Montgomery GW, Martin NG
(2005) Genomewide signiﬁcant linkage to migrainous headache
on chromosome 5q21. Am J Hum Genet 77:500–512
75. Soragna D, Vettori A, Carraro G, Marchioni E, Vazza G, Bellini
S, Tupler R, Savoldi F, Mostacciuolo ML (2003) A locus for
migraine without aura maps on chromosome 14q21.2–q22.3.
Am J Hum Genet 72:161–167
76. Nyholt DR, Curtain RP, Grifﬁths LR (2000) Familial typical
migraine: signiﬁcant linkage and localization of a gene to Xq24–
28. Hum Genet 107:18–23
77. McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ,
Hewett DR, Peroutka SJ, Grifﬁths LR, Boyd PR, Lea RA, Bhatti
SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R,
Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly
C, Lumsden SM, O’Sullivan J, See CG, Smart DH, Shaw-
Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG,
Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF,
Dykes C, Humphrey PP, Roses AD, Purvis IJ (2001) Single-
nucleotide polymorphism alleles in the insulin receptor gene are
associated with typical migraine. Genomics 78:135–149
78. Curtain R, Tajouri L, Lea R, MacMillan J, Grifﬁths L (2006) No
mutations detected in the INSR gene in a chromosome 19p13
linked migraine pedigree. Eur J Med Genet 49:57–62
79. Cupini LM, Massa R, Floris R, Manenti G, Martini B, Tessa A,
Nappi G, Bernardi G, Santorelli FM (2003) Migraine-like dis-
order segregating with mtDNA 14484 Leber hereditary optic
neuropathy mutation. Neurology 60:717–719
80. Ojaimi J, Katsabanis S, Bower S, Quigley A, Byrne E (1998)
Mitochondrial DNA in stroke and migraine with aura. Cere-
brovasc Dis 8:102–106
81. Majamaa K, Finnila ¨ S, Turkka J, Hassinen IE (1998) Mito-
chondrial DNA haplogroup U as a risk factor for occipital stroke
in migraine. Lancet 352:455–456
82. Boles RG, Williams JC (1999) Mitochondrial disease and cyclic
vomiting syndrome. Dig Dis Sci 44:103S–107S
83. Boles RG, Adams K, Ito M, Li BU (2003) Maternal inheritance
in cyclic vomiting syndrome with neuromuscular disease. Am J
Med Genet A 120:474–482
84. Salpietro CD, Briuglia S, Merlino MV, Di Bella C, Rigoli L
(2003) A mitochondrial DNA mutation (A3243G mtDNA) in a
family with cyclic vomiting. Eur J Pediatr 162:727–728
85. Russell MB, Ostergaard S, Bendtsen L, Olesen J (1999) Familial
occurrence of chronic tension-type headache. Cephalalgia
19:207–210
86. Cevoli S, Mochi M, Scapoli C, Marzocchi N, Pierangeli G, Pini
LA, Cortelli P, Montagna P (2006) A genetic association study
of dopamine metabolism-related genes and chronic headache
with drug abuse. Eur J Neurol 13:1009–1013
87. Mochi M, Cevoli S, Cortelli P, Pierangeli G, Scapoli C, Soriani
S, Montagna P (2003) Investigation of an LDLR gene poly-
morphism (19p13.2) in susceptibility to migraine without aura.
J Neurol Sci 213:7–10
88. Curtain R, Lea RA, Quinlan S, Bellis C, Tajouri L, Hughes R,
Macmillan J, Grifﬁths LR (2004) Investigation of the low-
density lipoprotein receptor gene and cholesterol as a risk factor
for migraine. J Neurol Sci 227:95–100
89. D’Amico D, Moschiano F, Leone M, Ariano C, Ciusani E, Erba
N, Grazzi L, Ferraris A, Schieroni F, Bussone G (1998) Genetic
abnormalities of the protein C system: shared risk factors in
66 J Headache Pain (2008) 9:57–69
123young adults with migraine with aura and with ischemic stroke?
Cephalalgia 18:618–621
90. Haan J, Kappelle LJ, de Ronde H, Ferrari MD, Bertina RM
(1997) The factor V Leiden mutation (R506Q) is not a major
risk factor for migrainous cerebral infarction. Cephalalgia
17:605–607
91. Corral J, Iniesta JA, Gonza ´lez-Conejero R, Lozano ML, Rivera
J, Vicente V (1998) Migraine and prothrombotic genetic risk
factors. Cephalalgia 18:257–260
92. Soriani S, Borgna-Pignatti C, Trabetti E, Casartelli A, Montagna
P, Pignatti PF (1998) Frequency of factor V Leiden in juvenile
migraine with aura. Headache 38:779–781
93. Haan J, Kappelle LJ, Ferrari MD, Bertina RM (1998) The
transition G to A at position 20210 in the 3’-untranslated region
of the prothrombin gene is not associated with migrainous
infarction. Cephalalgia 18:229–230
94. Iniesta JA, Corral J, Gonza ´lez-Conejero R, Dı ´az Ortun ˜oA ,
Martı ´nez Navarro ML, Vicente V (2001) Role of factor XIII Val
34 Leu polymorphism in patients with migraine. Cephalalgia
21:837–841
95. Paterna S, Di Pasquale P, D’Angelo A, Seidita G, Tuttolomondo
A, Cardinale A, Maniscalchi T, Follone G, Giubilato A, Tar-
antello M, Licata G (2000) Angiotensin-converting enzyme
gene deletion polymorphism determines an increase in fre-
quency of migraine attacks in patients suffering from migraine
without aura. Eur Neurol 43:133–136
96. Grifﬁths LR, Nyholt DR, Curtain RP, Goadsby PJ, Brimage PJ
(1997) Migraine association and linkage studies of an endo-
thelial nitric oxide synthase (NOS3) gene polymorphism.
Neurology 49:614–617
97. Lea RA, Curtain RP, Shepherd AG, Brimage PJ, Grifﬁths LR
(2001) No evidence for involvement of the human inducible
nitric oxide synthase (iNOS) gene in susceptibility to typical
migraine. Am J Med Genet 105:110–113
98. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG,
Alpe ´rovitch A (2001) Association between migraine and endo-
thelin type A receptor (ETA-231 A/G) gene polymorphism.
Neurology 56:1273–1277
99. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Naka-
shima K (2000) The homozygous C677T mutation in the
methylenetetrahydrofolate reductase gene is a genetic risk factor
for migraine. Am J Med Genet 96:762–764
100. Kara I, Sazci A, Ergul E, Kaya G, Kilic G (2003) Association of
the C677T and A1298C polymorphisms in the 5,10 methyl-
enetetrahydrofolate reductase gene in patients with migraine
risk. Brain Res Mol Brain Res 111:84–90
101. Oterino A, Valle N, Pascual J, Bravo Y, Mun ˜oz P, Castillo J,
Ruiz-Alegrı ´aC ,S a ´nchez- Velasco P, Leyva-Cobia ´n F, Cid C
(2005) Thymidylate synthase promoter tandem repeat and
MTHFD1 R653Q polymorphisms modulate the risk for
migraine conferred by the MTHFR T677 allele. Brain Res Mol
Brain Res 139:163–168
102. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith
CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic
distributions of the serotonin transporter gene in migraine
without aura and migraine with aura. Cephalalgia 18:23–26
103. Borroni B, Brambilla C, Liberini P, Rao R, Archetti S, Gipponi
S, Volta GD, Padovani A (2005) Functional serotonin
5-HTTLPR polymorphism is a risk factor for migraine with
aura. J Headache Pain 6:182–184
104. Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit
YA (2001) Signiﬁcance of serotonin transporter gene polymor-
phism in migraine. J Neurol Sci 186:27–30
105. Juhasz G, Zsombok T, Laszik A, Gonda X, Sotonyi P, Faludi G,
Bagdy G (2003) Association analysis of 5-HTTLPR variants,
5-HT2a receptor gene 102T/C polymorphism and migraine.
J Neurogenet 17:231–240
106. Monari L, Mochi M, Valentino ML, Arnaldi C, Cortelli P, De
Monte A, Pierangeli G, Prologo G, Scapoli C, Soriani S,
Montagna P (1997) Searching for migraine genes: exclusion of
290 cM out of the whole human genome. Ital J Neurol Sci
18:277–282
107. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Grifﬁths LR
(2000) Evidence for allelic association of the dopamine beta-
hydroxylase gene (DBH) with susceptibility to typical migraine.
Neurogenet 3:35–40
108. Erdal ME, Herken H, Yilmaz M, Bayazit YA (2001) Associa-
tion of the T102C polymorphism of 5-HT2A receptor gene with
aura in migraine. J Neurol Sci 188:99–101
109. Nyholt DR, Curtain RP, Gaffney PT, Brimage P, Goadsby PJ,
Grifﬁths LR (1996) Migraine association and linkage analyses
of the human 5-hydroxytryptamine (5HT2A) receptor gene.
Cephalalgia 16:463–467
110. Buchwalder A, Welch SK, Peroutka SJ (1996) Exclusion of
5-HT2A and 5-HT2C receptor genes as candidate genes for
migraine. Headache 36:254–258
111. Johnson MP, Lea RA, Curtain RP, MacMillan JC, Grifﬁths LR
(2003) An investigation of the 5-HT2C receptor gene as a
migraine candidate gene. Am J Med Genet B Neuropsychiatr
Genet 117:86–89
112. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD,
Saxena PR (1998) Coronary side-effect potential of current and
prospective antimigraine drugs. Cirgulation 98:25–30
113. MaassenVanDenBrink A, Vergouve MN, Ophoff RA, Saxena
PR, Ferrari MD, Frants RR (1998) 5-HT1B receptor polymor-
phism and clinical response to sumatriptan. Headache 38:288–
291
114. Peroutka SJ, Price SC, Wilhoit TL, Jones KW (1998) Comorbid
migraine with aura, anxiety, and depression is associated with
dopamine D2 receptor (DRD2) NcoI alleles. Mol Med 4:14–21
115. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A,
Gessa GL, Piccardi MP (1998) Association between dopamine
receptor genes and migraine without aura in a Sardinian sample.
Neurology 51:781–786
116. Dichgans M, Fo ¨rderreuther S, Deiterich M, Pfaffenrath V,
Gasser T (1998) The D2 receptor NcoI allele: absence of allelic
association with migraine with aura. Neurology 51(3):928
117. Montagna P, Cevoli S, Marzocchi N, Pierangeli G, Pini LA,
Cortelli P, Mochi M (2003) The genetics of chronic headaches.
Neurol Sci 24:S51–S56
118. Maude S, Curtin J, Breen G, Collier D, Russell G, Shaw D, Clair
DS (2001) The -141C Ins/Del polymorphism of the dopamine
D2 receptor gene is not associated with either migraine or
Parkinson’s disease. Psychiatr Genet 11:49–52
119. Rebaudengo N, Rainero I, Parziale A, Rosina F, Pavanelli E,
Rubino E, Mazza C, Ostacoli L, Furlan PM (2004) Lack of
interaction between a polymorphism in the dopamine D2
receptor gene and the clinical features of migraine. Cephalalgia
24:503–507
120. Shepherd AG, Lea RA, Hutchins C, Jordan KL, Brimage PJ,
Grifﬁths LR (2002) Dopamine receptor genes and migraine with
and without aura: an association study. Headache 42:346–351
121. Marziniak M, Mo ¨ssner R, Benninghoff J, Syagailo YV, Lesch
KP, Sommer C (2004) Association analysis of the functional
monoamine oxidase A gene promotor polymorphism in
migraine. J Neural Transm 111:603–609
122. Fernandez F, Lea RA, Colson NJ, Bellis C, Quinlan S, Grifﬁths
LR (2006) Association between a 19 bp deletion polymorphism
at the dopamine beta-hydroxylase (DBH) locus and migraine
with aura. J Neurol Sci 251:118–123
J Headache Pain (2008) 9:57–69 67
123123. Mochi M, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Scapoli
C, Montagna P (2003) A genetic association study of migraine
with dopamine receptor 4, dopamine transporter and dopamine-
beta-hydroxylase genes. Neurol Sci 23:301–305
124. Colson NJ, Lea RA, Quinlan S, MacMillan J, Grifﬁths LR
(2005) Investigation of hormone receptor genes in migraine.
Neurogenetics 6:17–23
125. Mo ¨ssner R, Weichselbaum A, Marziniak M, Freitag CM, Lesch
KP, Sommer C, Meyer J (2005) A highly polymorphic poly-
glutamine stretch in the potassium channel KCNN3 in migraine.
Headache 45:132–136
126. Curtain R, Sundholm J, Lea R, Ovcaric M, MacMillan J, Grif-
ﬁths L (2005) Association analysis of a highly polymorphic
CAG Repeat in the human potassium channel gene KCNN3 and
migraine susceptibility. BMC Med Genet 14:32–39
127. Lulli P, Trabace S, Morellini M, Cicciarelli G, Coloprisco G,
Piane M, de Filippis S, Santi PG, Avramakou O, Ferlicca E,
Martelletti P (2005) Cytotoxic T lymphocyte antigen 4 poly-
morphism 49 (A[G) and migraine. J Headache Pain 6:188–
190
128. Rainero I, Fasano E, Rubino E, Rivoiro C, Valfre ` W, Gallone S,
Savi L, Gentile S, Lo Giudice R, De Martino P, Dall’Omo AM,
Pinessi L (2005) Association between migraine and HLA-DRB1
gene polymorphisms. J Headache Pain 6:185–187
129. Couturier EG, Hering R, Steiner TJ (1991) The ﬁrst report of
cluster headache in identical twins. Neurology 41:761
130. Roberge C, Bouchard JP, Simard D, Gagne ´ R (1992) Cluster
headache in twins. Neurology 42:1255–1256
131. Schuh-Hofer S, Meisel A, Reuter U, Arnold G (2003) Mono-
zygotic twin sisters suffering from cluster headache and
migraine without aura. Neurology 60:1864–1865
132. Sjaastad O, Shen JM, Stovner LJ, Elsa ˚s T (1993) Cluster
headache in identical twins. Headache 33:214–217
133. Spierings EL, Vincent AJ (1992) Familial cluster headache:
occurrence in three generations. Neurology 42:1399–1400
134. Alberca R, Aguilera JM, Casado JL, Lo ´pez JM, Arenas C,
Moreno A, Serrano V (1994) Cluster headache with a familial
presentation. Neurologia 9:22–24
135. Bordini CA, Arruda MA, Ciciarelli M, Daripa M, Martins
Coelho J, Speciali JG (1997) Cluster headache: report of seven
cases in three families. Funct Neurol 12:277–282
136. D’Amico D, Leone M, Moschiano F, Bussone G (1996) Familial
cluster headache: report of three families. Headache 36:41–43
137. De Simone R, Fiorillo C, Bonuso S, Castaldo G (2003) A cluster
headache family with possible autosomal recessive inheritance.
Neurology 61:578–579
138. Russell MB, Andersson PG, Thomsen LL (1995) Familial
occurrence of cluster headache. J Neurol Neurosurg Psychiatry
58:341–343
139. Russell MB, Andersson PG, Thomsen LL, Iselius L (1995)
Cluster headache is an autosomal dominantly inherited disorder
in some families: a complex segregation analysis. J Med Genet
32:954–956
140. Russell MB, Andersson PG, Iselius L (1996) Cluster headache is
an inherited disorder in some families. Headache 36:608–612
141. Montagna P, Mochi M, Prologo G, Sangiorgi S, Pierangeli G,
Cavoli S, Cortelli P (1998) Heritability of cluster headache. Eur
J Neurol 5:343–345
142. Russell MB (2004) Epidemiology and genetics of cluster
headache. Lancet Neurol 3:279–283
143. El Amrani M, Ducros A, Boulan P, Aidi S, Crassard I, Visy JM,
Tournier-Lasserve E, Bousser MG (2002) Familial cluster
headache: a series of 186 index patients. Headache 42:974–977
144. Svensson D, Ekbom K, Pedersen NL, Tra ¨ff H, Waldenlind E
(2003) A note on cluster headache in a population-based twin
register. Cephalalgia 23:376–380
145. Shimomura T, Kitano A, Marukawa H, Mishima K, Isoe K,
Adachi Y, Takahashi K (1994) Point mutation in platelet
mitochondrial tRNA (Leu(UUR)) in patient with cluster head-
ache. Lancet 344:625
146. Cortelli P, Zacchini A, Barboni P, Malpassi P, Carelli V,
Montagna P (1995) Lack of association between mitochondrial
tRNA(Leu(UUR)) point mutation and cluster headache. Lancet
345:1120–1121
147. Seibel P, Gru ¨newald T, Gundolla A, Diener HC, Reichmann H
(1996) Investigation on the mitochondrial transfer RNA(-
Leu)(UUR) in blood cells from patients with cluster headache. J
Neurol 243:305–307
148. Odawara M, Tamaoka A, Mizusawa H, Yamashita K (1997) A
case of cluster headache associated with mitochondrial DNA
deletions. Muscle Nerve 20:394–395
149. Cuypers J, Altenkirch H (1979) HLA antigens in cluster head-
ache. Headache 19:228–229
150. Martelletti P, Romiti A, Gallo MF, Giacovazzo M, Adorno D,
Valeri M, Piazza A, Monaco PI, Casciani CU (1984) HLA-B14
antigen in cluster headache. Headache 24:152–154
151. Giacovazzo M, Martelletti P, Romiti A, Gallo MF, Iuvara E,
Valeri M, Piazza A, Adorno D, Monaco PI, Casciani CU (1986)
Genetic markers of cluster headache and the links with the
lithium salts therapy. Int J Clin Pharmacol Res 6:19–22
152. Sjo ¨strand C, Giedratis V, Ekbom K, Waldenlind E, Hillert J
(2001) CACNA1A gene polymorphisms in cluster headache.
Cephalalgia 21:953–958
153. Haan J, van Vliet JA, Kors EE, Terwindt GM, Vermeulen FL,
van den Maagdenberg AM, Frants RR, Ferrari MD (2001) No
involvement of the calcium channel gene (CACNA1A) in a
family with cluster headache. Cephalalgia 21:959–962
154. Sjo ¨strand C, Modin H, Masterman T, Ekbom K, Waldenlind E,
Hillert J (2002) Analysis of nitric oxide synthase genes in cluster
headache. Cephalalgia 22:758–764
155. Aridon P, D’Andrea G, Rigamonti A, Leone M, Casari G,
Bussone G (2004) Elusive amines and cluster headache: muta-
tional analysis of trace amine receptor cluster on chromosome
6q23. Neurol Sci 25(Suppl 3):S279–S280
156. Cevoli S, Mochi M, Pierangeli G, Zanigni S, Grimaldi D,
Bonavina G, Torelli P, Manzoni GC, Cortelli P, Montagna P
(2008) Investigation of the T3111C CLOCK gene polymor-
phism in cluster headache. J Neurol Feb 20 [Epub ahead of
print]
157. Rainero I, Rivoiro C, Gallone S, Valfre ` W, Ferrero M, Angilella
G, Rubino E, De Martino P, Savi L, Lo Giudice R, Pinessi L
(2005) Lack of association between the 3092 T?C Clock gene
polymorphism and cluster headache. Cephalalagia 25:1078–
1081
158. Rainero I, Rivoiro C, Rubino E, Milli V, Valfre ` W, De Martino
P, Lo Giudice R, Angilella G, Savi L, Gallone S, Pinessi L
(2005) Prevalence of HFE (hemochromatosis) gene mutations in
patients with cluster headache. Headache 45:1219–1223
159. Rainero I, Gallone S, Valfre ` W, Ferrero M, Angilella G, Rivoiro
C, Rubino E, De Martino P, Savi L, Ferrone M, Pinessi L (2004)
A polymorphism of the hypocretin receptor 2 gene is associated
with cluster headache. Neurology 63:1286–1288
160. Schu ¨rks M, Kurth T, Geissler I, Tessmann G, Diener HC,
Rosskopf D (2006) Cluster headache is associated with the
G1246A polymorphism in the hypocretin receptor 2 gene.
Neurology 66:1917–1919
161. Baumber L, Sjo ¨strand C, Leone M, Harty H, Bussone G, Hillert
J, Trembath RC, Russell MB (2006) A genome-wide scan and
HCRTR2 candidate gene analysis in a European cluster head-
ache cohort. Neurology 66:1888–1893
162. Siow HC, Young WB, Peres MF, Rozen TD, Silberstein SD
(2002) Hemiplegic cluster. Headache 42:136–139
68 J Headache Pain (2008) 9:57–69
123163. Sjo ¨strand C, Duvefelt K, Steinberg A, Remahl IN, Waldenlind
E, Hillert J (2006) Gene expression proﬁling in cluster head-
ache: a pilot microarray study. Headache 46:1518–1534
164. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar
ML, Heine-Sun ˜er D, Cigudosa JC, Urioste M, Benitez J, Boix-
Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P,
Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M
(2005) Epigenetic differences arise during the lifetime of
monozygotic twins. Proc Natl Acad Sci USA 102:10604–10609
165. Oommen AM, Grifﬁn JB, Sarath G, Zempleni J (2005) Roles for
nutrients in epigenetic events. J Nutr Biochem 16:74–77
166. Champagne FA, Francis DD, Mar A, Meaney MJ (2003) Vari-
ations in maternal care in the rat as a mediating inﬂuence for the
effects of environment on development. Physiol Behav 79:359–
371
167. Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma
S, Seckl JR, Dymov S, Szyf M, Meaney MJ (2004) Epigenetic
programming by maternal behavior. Nat Neurosci 7:847–854
168. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S,
Meaney MJ, Szyf M (2005) Reversal of maternal programming
of stress responses in adult offspring through methyl supple-
mentation: altering epigenetic marking later in life. J Neurosci
25:11045–11054
169. Karten YJ, Olariu A, Cameron HA (2005) Stress in early life
inhibits neurogenesis in adulthood. Trends Neurosci 28:171–172
170. Vicentic A, Francis D, Moffett M, Lakatos A, Rogge G, Hubert
GW, Harley J, Kuhar MJ (2006) Maternal separation alters
serotonergic transporter densities and serotonergic 1A receptors
in rat brain. Neuroscience 140:355–365
171. Burlet G, Fernette B, Blanchard S, Angel E, Tankosic P, Mac-
cari S, Burlet A (2005) Antenatal glucocorticoids blunt the
functioning of the hypothalamic–pituitary–adrenal axis of neo-
nates and disturb some behaviors in juveniles. Neuroscience
133:221–230
172. Yoshihara T, Otsuki Y, Yamazaki A, Honma S, Yamasaki Y,
Honma K (2005) Maternal deprivation in neonatal rats alters the
expression of circadian system under light–dark cycles and
restricted daily feeding in adulthood. Physiol Behav 85:646–654
173. Levenson JM, Sweatt JD (2005) Epigenetic mechanisms in
memory formation. Nat Rev Neurosci 6:108–118
174. Hong EJ, West AE, Greenberg ME (2005) Transcriptional
control of cognitive development. Curr Opin Neurobiol 15:21–
28
175. Petronis A (2004) The origin of schizophrenia: genetic thesis,
epigenetic antithesis, and resolving synthesis. Biol Psychiatry
55:965–970
176. Gottesman II, Hanson DR (2005) Human development: bio-
logical and genetic processes. Annu Rev Psychol 56:263–286
177. Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated
epigenetic and genetic approach to common human disease.
Trends Genet 20:350–358
178. Jirtle RL, Skinner MK (2007) Environmental epigenomics and
disease susceptibility. Nat Rev Genet 8:253–262
179. Vercelli D (2004) Genetics, epigenetics, and the environment:
switching, buffering, releasing. J Allergy Clin Immunol
113:381–386
180. Savi L, Buccheri R, Tambornini A, De Martino P, Albasi C,
Pinessi L (2005) Attachment styles and headache. J Headache
Pain 6:254–257
181. Rossi P, Di Lorenzo G, Malpezzi MG, Di Lorenzo C, Cesarino
F, Faroni J, Siracusano A, Troisi A (2005) Depressive symptoms
and insecure attachment as predictors of disability in a clinical
population of patients with episodic and chronic migraine.
Headache 45:561–570
182. Ventegodt S, Flensborg-Madsen T, Andersen NJ, Merrick J
(2005) Events in pregnancy, delivery, and infancy and long-term
effects on global quality of life: results from the Copenhagen
Perinatal Birth Cohort 1959–61. Med Sci Monit 11:CR357–
CR365
183. Blau JN (1992) Migraine: theories of pathogenesis. Lancet
339:1202–1209
184. Welch KM (1986) Migraine: a biobehavioural disorder. Ceph-
alalgia 6:103–110
185. Montagna P, Cortelli P (2008) Migraine and the autonomic
nervous system. In: Low PA (ed) Clinical autonomic disorders:
evaluation and management. Lippincott, Williams and Wilkins,
Philadelphia (in press)
186. Hart BL (1988) Biological basis of the behavior of sick animals.
Neurosci Biobehav Rev 12:123–137
187. Blau JN (1993) Behaviour during a cluster headache. Lancet
342:723–725
188. Loder E (2002) What is the evolutionary advantage of migraine?
Cephalalgia 22:624–32
J Headache Pain (2008) 9:57–69 69
123